HAYWARD, Calif., Sept. 26 /PRNewswire/ -- Singulex, Inc. today announced that Stanford University has granted Singulex an exclusive, worldwide license under the patent covering Stanford’s technology for the ultrasensitive detection of an individual fluorescent particle at a single molecule limit.
The technology, invented by Lubert Stryer, Richard Mathies and Konan Peck, is covered by U.S. Patent No. 4,979,824 entitled “High sensitivity fluorescent single particle and single molecule detection apparatus and method” and was issued by the U.S. Patent and Trademark Office to Leland Stanford Junior University, who has granted exclusive worldwide rights to Singulex for the patent. Technology in the patent will enable Singulex to conduct quantitative detection of single molecules in fluid solutions as well as on a surface or film.
“This is an important technology for any company developing sensitive biomarker detection systems,” said Philippe Goix, president and CEO of Singulex. “Integrating this technology into our molecule detection platforms will enhance our biomarker discovery and validation programs and enable Singulex and our pharmaceutical partners to conduct more efficient drug discovery and development.”
Singulex has incorporated the Stanford technology into the company’s flagship quantitative digital molecule detection platform, the Zeptx(TM) System. The Zeptx System incorporates a variety of well-established detection and unique tagging technologies to create a powerful system that can measure target biomarkers with a high degree of sensitivity, accuracy and precision from biological samples including serum in under an hour. The analytic power of the Zeptx System has been proven in pilot studies and Singulex expects to launch the Zeptx System for installation into customer sites in the first half of 2007.
About Singulex
Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company’s leading digital molecule detection platfom, the Zeptx(TM) System, which will be commercially available in the first half of 2007. To learn more about Singulex or the Zeptx System, please visit us at www.singulex.com.
Singulex, Inc.
CONTACT: Amy Blackley, Ph.D., Porter Novelli Life Sciences,+1-619-849-6008, ablackley@pnlifesciences.com, for Singulex, Inc.
Web site: http://www.singulex.com/
